Anti-CXCR5 Antibody Formulations for High-Concentration Storage Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pharmaceutical formulations containing high concentrations of anti-CXCR5 binding agents face issues such as increased viscosity, pH shift, solution color change, formation of visible and sub-visible particles, and interaction with storage containers, necessitating improved formulations with enhanced storage stability.
Innovation Solution
Development of anti-CXCR5 antibody formulations with specific excipients that maintain stability in glass storage containers, including citrate buffer, polysorbate 20, sucrose, and arginine, to prevent particle formation and maintain formulation integrity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high concentrations of anti-CXCR5 binding agents (20-250 mg/mL) are used in pharmaceutical formulations, then therapeutic efficacy is improved, but particle formation and aggregation increase
Solution Approach 1:
The patent introduces polysorbate 20 as a surfactant intermediary that mediates between the high concentration binding agent and the storage environment, preventing particle formation by reducing surface tension and preventing aggregation at the air-liquid interface and throughout the solution
Solution Approach 2:
The patent modifies the formulation parameters by adjusting pH (using citrate buffer to maintain pH 3.0-6.0), adding stabilizing agents (sucrose and arginine), and optimizing surfactant concentration to enable high binding agent concentrations without particle formation
2Quantity of substance
If high concentrations of anti-CXCR5 binding agents are formulated, then dosing efficiency is improved, but viscosity increases
Solution Approach 1:
The patent changes the formulation parameters by incorporating specific excipients (polysorbate 20, citrate buffer, sucrose, arginine) that modify the solution's physical properties, allowing high binding agent concentrations to be achieved while maintaining acceptable viscosity through molecular interactions and steric stabilization
3Quantity of substance
If high concentrations of anti-CXCR5 binding agents are used, then treatment effectiveness is improved, but pH stability deteriorates
Solution Approach 1:
The patent introduces citrate buffer as a pH-stabilizing intermediary that mediates between the binding agent and the aqueous environment, absorbing pH fluctuations and maintaining stable conditions even at high binding agent concentrations where self-aggregation would otherwise occur
4Reliability
If binding agents are stored in glass containers, then storage stability is improved, but interaction between formulation and container increases
Solution Approach 1:
The patent introduces polysorbate 20 as a surfactant intermediary that adsorbs to glass surfaces and forms a protective barrier, preventing direct interaction between the binding agent and the glass container while maintaining storage stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations exhibit increased storage stability, reducing particle formation and maintaining biological activity over time, suitable for intravenous or subcutaneous administration.
Implementation Method 1
formulations with anti-CXCR5 antibodies, citrate buffer, polysorbate 20, sucrose and arginine
Implementation Method 2
formulations with anti-CXCR5 antibodies, citrate buffer, polysorbate 20, sucrose and arginine
Implementation Method 3
formulations with anti-CXCR5 antibodies, citrate buffer, polysorbate 20, sucrose and arginine
Data Source
Figure 1~3
Figure 4~5
Figure 6~8
AI summary
High concentration antibody formulations capable of stable long-term storage are disclosed.